What is Neurosteer?
Neurosteer is at the forefront of developing advanced medical-grade technology for brain activity interpretation. Their flagship product, hdrEEG, is a compact platform designed for the early detection of cognitive decline and neurological disorders such as Parkinson's, Alzheimer's, and epilepsy. By offering real-time analysis and objective biomarkers, Neurosteer aims to establish a new standard in brain health diagnostics, making advanced monitoring more accessible and affordable for both clinical settings and remote patient care. The company's strategic focus is on enabling earlier and more effective treatment interventions.
How much funding has Neurosteer raised?
Neurosteer has raised a total of $44K across 1 funding round:
Debt
$44K
Debt (2021): $44K with participation from PPP
What's next for Neurosteer?
With significant Series B/C stage funding, Neurosteer is poised for substantial expansion. The recent capital infusion is expected to accelerate product development, enhance market penetration, and potentially broaden the application of their hdrEEG platform. This strategic investment will likely support scaling operations, further clinical validation, and expanding their reach to a wider patient demographic and healthcare provider network. The company's trajectory suggests a strong emphasis on solidifying its position as a leader in accessible neurological diagnostics.
See full Neurosteer company page
